The Outbreak of Covid-19 and the Prevalence of Infectious and Chronic Diseases are Increasing the Demand for Serological Testing

calendar_today 06 October, 2022 person_outline Growth Plus Reports

According to the deep-dive market assessment study by Growth+ Reports, the global serological testing market was valued at ~US$ 3.1 billion in 2021. The market is expected to witness a CAGR of ~9.0 % from 2022 to 2030.  

Serological testing, also known as immunoassay testing, detects the presence of antibodies or antigens in blood serum. Antigens are foreign substances that cause disease and stimulate the immune system. Serological testing is most commonly used to diagnose parasitic, viral, and bacterial infections such as dengue, malaria, hepatitis, HIV, and others. It validates antibodies and antigens for analyzing a specific disease or condition and allows doctors to provide appropriate medical treatment. Various serological test methods are used for disease detection, including hemagglutinin-inhibition tests, enzyme-linked immunosorbent assays (ELISAs), flocculation tests, neutralization tests, and chemiluminescence immunoassays. 

HIV (human immunodeficiency virus) attacks immune cells responsible for fighting antigens and infections. The late stage of HIV results in acquired immunodeficiency syndrome (AIDS), the most severe condition in which the immune system is severely damaged. The infected person experiences sudden weight loss and is more likely to develop diseases that would not commonly occur in a healthy person. As a result, regular testing is required to monitor viral load. HIV is diagnosed using a rapid antigen test, western blot method, ELISA testing, and RTPCR. According to the Centers for Disease Control and Prevention, nearly 34,800 new HIV cases were reported in the United States in 2019. It is estimated that in 2019 around 1,189,700 people in the United States had HIV. The increasing number of HIV-infected patients and high HIV transmission rate contribute to the growth of the global serological testing market.
  
Hepatitis B is a serious and highly transmittable viral disease that can cause severe liver damage and is responsible for chronic liver diseases. Many people who have hepatitis have no symptoms. All three types of hepatitis symptoms are very similar: the dark color of urine, stomach ache, skin or eye yellowing, stool in a light or clay color, fever of moderate frequency, and appetite loss.

According to The World Health Organization, in 2019, nearly 296 million people were living with chronic hepatitis B, and almost 1.5 million new infection cases were reported yearly. In 2019, hepatitis B caused 820,000 deaths, mostly from primary liver cancer. The significant burden of the prevalence of hepatitis B is increasing the demand for diagnostic tests, thus contributing to the growth of the global serological testing market. 

However, limited reimbursement policies for diagnosis, the risk of false positive outcomes, and expensive genome testing are slowing the growth of the global serological testing market. For genome testing, genome sequencer equipment is required, which costs between US$ 800,000 and US$ 900,000, and requires at least 100-200 samples to run the sequencing process on the testing chip. Even if you have a lower sample count, the chip will still cost the same. Furthermore, high sample rejection due to the inability to meet quality standards makes genome sequencing tests expensive.

The region's global serological testing market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America dominated the global serological testing market. The large share of North America in the global serological testing market is attributed to the high incidence of infectious diseases, i.e., HIV, hepatitis, etc., and the outbreak of COVID-19. Additionally, the presence of developed infrastructure, high healthcare expenditure, favorable government policies, easy uptake of technological advancements, and introduction of novel serological testing methodologies contribute to the growth of the North American serological testing market. The Asia Pacific is also expected to show a noticeable change in the serological testing market owing to a large population and prevalence of infectious diseases. Additionally, swift development in the healthcare infrastructure and growing penetration of international giants in the emerging economies of Asia Pacific also drive the serological testing market in the region. 

Some prominent players operating in the global serological testing market are Abbott Laboratories Inc, Quidel Corporation, Beckman Coulter, Inc., Becton Merck KGaA, bioMérieux SA, Grifols, S.A., DiaSorin S.p.A, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Mylab Discovery Solutions Pvt. Ltd., Tulip Diagnostics Ltd. (PerkinElmer Inc.), Siemens Healthineers AG, Sysmex Corporation, Becton, Dickinson & Co., and Thermo Fisher Scientific Inc. among others.

awards awards key differentiators

Reach Us

enquire@growthplusreports.com

Web –  www.growthplusreports.com

// // // //